Race differences: Modeling the pharmacodynamics of rosuvastatin in Western and Asian hypercholesterolemia patients

Acta Pharmacologica Sinica

Volumn 32, Issue 1, 2011, Pages 116-125

  Yang, Juan ^a   Li, Lu Jin ^a   Wang, Kun ^a   He, Ying Chun ^a   Sheng, Yu Cheng ^a   Xu, Ling ^a   Huang, Xiao Hui ^b   Guo, Feng ^c   Zheng, Qing Shan ^a  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b ANHUI MEDICAL UNIVERSITY   (China)

^c PFIZER INC   (United States)

Author keywords

clinical trial; dose response relationship; LDL; race difference; rosuvastatin; ypercholesterolemia

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN;

ARTICLE; ASIAN; DOSE RESPONSE; HUMAN; HYPERCHOLESTEROLEMIA; MOLECULAR MODEL; PHARMACODYNAMICS; POPULATION MODEL; RACE DIFFERENCE;

ANTICHOLESTEREMIC AGENTS; ASIA; ASIAN CONTINENTAL ANCESTRY GROUP; CHOLESTEROL, LDL; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHNOPHARMACOLOGY; EUROPEAN CONTINENTAL ANCESTRY GROUP; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MODELS, BIOLOGICAL; PYRIMIDINES; SULFONAMIDES;

EID: 78651069386     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2010.169     Document Type: Article

References (52)

1. Olsson AG, Pears J, McKellar J, Mizan J, Raza A. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol 2001; 88: 504-8.
2. Paoletti R, Fahmy M, Mahla G, Mizan J, Southworth H. Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: A randomized, double-blind study. J Cardiovasc Risk 2001; 8: 383-90.
3. Olsson AG, Istad H, Luurila O, Ose L, Stender S, Tuomilehto J, et al. Effects of rosuvastatin compared over 52 weeks for treatment in patients with hypercholesterolemia. Am Heart J 2002; 144: 1044-51.
4. Carswell CI, Plosker GL, Jarvis B. Rosuvastatin. Drugs 2002; 62: 2075-85.
5. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLA.R.* Trial). Am J Cardiol 2003; 92: 152-60.
6. Rader DJ, Davidson MH, Caplan RJ, Pears JS. Lipid and apolipoprotein ratios: Association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin. Am J Cardiol 2003; 91: 20C-23C.
7. McTaggart F, Buckett L, Davidson R, Holdgate G, McCormick A, Schneck D, et al. Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol 2001; 87: 28B-32B.
8. Leonard KA. Treatment and prevention of dyslipidemia with rosuvastatin (Crestor). Nurse Pract 2004; 29: 11-5.
9. Martin PD, Warwick MJ, Dane AL, Cantarini MV. A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers. Clin Ther 2003; 25: 2215-24.
10. Martin PD, Dane AL, Nwose OM, Schneck DW, Warwick MJ. No effect of age or gender on the pharmacokinetics of rosuvastatin: A new HMG-CoA reductase inhibitor. J Clin Pharmacol 2002; 42: 1116-21.
11. Tzeng TB, Schneck DW, Birmingham BK, Mitchell PD, Zhang H, Martin PD, et al. Population pharmacokinetics of rosuvastatin: Implications of renal impairment, race, and dyslipidaemia. Curr Med Res Opin 2008; 24: 2575-85.
12. AstraZeneca Canada Inc. PRODUCT MONOGRAPH. Pr CRESTOR ® rosuvastatin. Tablets, 5, 10, 20, and 40 mg. LIPID METABOLISM REGULATOR [monograph on the Internet]. 2008 [cited 2009 May 7]. Available from: Http://www.astrazeneca.ca/ documents/ ProductPortfolio/CRESTOR-PM-en.pdf.
13. Lee E, Ryan S, Birmingham B, Zalikowski J, March R, Ambrose H, et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 2005; 78: 330-41.
14. Saito Y, Goto Y, Dane A, Strutt K, Raza A. Randomized dose-response study of rosuvastatin in Japanese patients with hypercholesterolemia. J Atheroscler Thromb 2003; 10: 329-36.
15. Mandema JW, Hermann D, Wang W, Sheiner T, Milad M, Bakker Arkema R, et al. Model-based development of gemcabene, a new lipid-altering agent. AAPS J 2005; 7: E513-22.
16. Mandema JW, Verotta D, Sheiner LB. Building population pharmacokinetic - pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm 1992; 20: 511-28.
17. Beal SL, Sheiner LB. NONMEM Users Guides. San Francisco: NONMEM Project Group, University of California, San Francisco, CA. 1989.
18. Ette EI. Stability and performance of a population pharmacokinetic model. J Clin Pharmacol 1997; 37: 486-95
19. Ishibashi T, Yano Y, Oguma T. Population pharmacokinetics of platinum after nedaplatin administration and model validation in adult patients. Br J Clin Pharmacol 2003; 56: 205-13.
20. Davidson M, Ma P, Stein EA, Gotto AM Jr, Raza A, Chitra R, et al. Comparison of effects on low-density lipoprotein cholesterol and highdensity lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol 2002; 89: 268-75.
21. Brown WV, Bays HE, Hassman DR, McKenney J, Chitra R, Hutchinson H, et al. Efficacy and safety of Rosuvastatin compared with Pravastatin and Simvastatin in patients with hypercholesterolemia: A randomized, double-blind, 52-week trial. Am Heart J 2002; 144: 1036-43.
22. Schneck DW, Knopp RH, Ballantyne CM, McPherson R, Chitra RR, Simonson SG. Comparative effects of Rosuvastatin and Atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease. Am J Cardiol 2003; 91: 33-41.
23. Schwartz GG, Bolognese MA, Tremblay BP, Caplan R, Hutchinson H, Raza A, et al. Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: A randomized, controlled trial. Am Heart J 2004; 148: E4.
24. Catapano AL, Davidson MH, Ballantyne CM, Brady WE, Gazzara RA, Tomassini JE, et al. Lipid-altering efficacy of the ezetimibe/ simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Curr Med Res Opin 2006; 22: 2041-53.
25. Yamamoto A, Arakawa K, Sasaki J, Matsuzawa Y, Takemura K, Tsushima M, et al. Clinical effects of rosuvastatin, a new HMG-CoA reductase inhibitor, in Japanese patients with primary hypercholesterolemia: An early phase II study. J Atheroscler Thromb 2002; 9: 48-56.
26. Deedwania PC, Gupta M, Stein M, Ycas J, Gold A; IRIS Study Group. Comparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS Trial). Am J Cardiol 2007; 99: 1538-43.
27. Kosoglou T, Statkevich P, Yang B, Suresh R, Zhu Y, Boutros T, et al. Pharmacodynamic interaction between ezetimibe and rosuvastatin. Curr Med Res Opin 2004; 20: 1185-95.
28. Strandberg TE, Feely J, Sigurdsson EL; DISCOVERY study group. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: A DISCOVERY study. Clin Ther 2004; 26: 1821-33.
29. Ballantyne CM, Miller E, Chitra R. Efficacy and safety of rosuvastatin alone and in combination with cholestyramine in patients with severe hypercholesterolemia: A randomized, open-label, multicenter trial. Clin Ther 2004; 26: 1855-64.
30. Cheung RC, Morrell JM, Kallend D, Watkins C, Schuster H. Effects of switching statins on lipid and apolipoprotein ratios in the MERCURY I study. Int J Cardiol 2005; 100: 309-16.
31. Fonseca FA, Ruiz A, Cardona-Munoz EG, Silva JM, Fuenmayor N, Marotti M, et al. The DISCOVERY PENTA study: A DIrect Statin Comparison of LDL-C Value - an Evaluation of Rosuvastatin therapY compared with atorvastatin. Curr Med Res Opin 2005; 21: 1307-15.
32. Bots AF, Kastelein JJ; Discovery Netherlands Investigators. Achieving lipid goals in real life: The Dutch DISCOVERY study. Int J Clin Pract 2005; 59: 1387-94.
33. Leiter LA, Rosenson RS, Stein E, Reckless JP, Schulte KL, Schleman M, et al. Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: Results of the POLARIS study. Atherosclerosis 2007; 194: E154-64.
34. Ballantyne CM, Weiss R, Moccetti T, Vogt A, Eber B, Sosef F, et al. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am J Cardiol 2007; 99: 673-80.
35. Asztalos BF, Le Maulf F, Dallal GE, Stein E, Jones PH, Horvath KV, et al. Comparison of the effects of high doses of rosuvastatin versus atorvastatin on the subpopulations of high-density lipoproteins. Am J Cardiol 2007; 99: 681-5.
36. Talini E, Di Bello V, Bianchi C, Palagi C, Delle Donne MG, Penno G, et al. Early impairment of left ventricular function in hypercholesterolemia and its reversibility after short term treatment with rosuvastatin A preliminary echocardiographic study. Atherosclerosis 2008; 197: 346-54.
37. Sviridov D, Hoang A, Ooi E, Watts G, Barrett PH, Nestel P. Indices of reverse cholesterol transport in subjects with metabolic syndrome after treatment with rosuvastatin. Atherosclerosis 2008; 197: 732-9.
38. Betteridge DJ, Gibson JM, Sager PT. Comparison of effectiveness of rosuvastatin versus atorvastatin on the achievement of combined C-reactive protein (<2 mg/L) and low-density lipoprotein cholesterol (<70 mg/dl) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA study). Am J Cardiol 2007; 100: 1245-8.
39. Stein EA, Amerena J, Ballantyne CM, Brice E, Farnier M, Guthrie RM, et al. Long-term efficacy and safety of rosuvastatin 40 mg in patients with severe hypercholesterolemia. Am J Cardiol 2007; 100: 1387-96.
40. Laks T, Keba E, Leiner M, Merilind E, Petersen M, Reinmets S, et al. Achieving lipid goals with rosuvastatin compared with simvastatin in high risk patients in real clinical practice: A randomized, open-label, parallel-group, multi-center study: The DISCOVERY-Beta study. Vasc Health Risk Manag 2008; 4: 1407-16.
41. Underhill HR, Yuan C, Zhao XQ, Kraiss LW, Parker DL, Saam T, et al. Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: A highresolution magnetic resonance imaging trial. Am Heart J 2008; 155: 584.e1-8.
42. Faergeman O, Hill L, Windler E, Wiklund O, Asmar R, Duffield E, et al. Efficacy and tolerability of rosuvastatin and atorvastatin when forcetitrated in patients with primary hypercholesterolemia: Results from the ECLIPSE study. Cardiology 2008; 111: 219-28.
43. Mazza F, Stefanutti C, Di Giacomo S, Vivenzio A, Fraone N, Mazzarella B, et al. Effects of low-dose atorvastatin and rosuvastatin on plasma lipid profiles: A long-term, randomized, open-label study in patients with primary hypercholesterolemia. Am J Cardiovasc Drugs 2008; 8: 265-70.
44. Pirro M, Schillaci G, Romagno PF, Mannarino MR, Bagaglia F, Razzi R, et al. Influence of short-term rosuvastatin therapy on endothelial progenitor cells and endothelial function. J Cardiovasc Pharmacol Ther 2009; 14: 14-21.
45. Lu TM, Ding YA, Leu HB, Yin WH, Sheu WH, Chu KM. Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia. Am J Cardiol 2004; 94: 157-61.
46. Wongwiwatthananukit S, Sansanayudh N, Dhummauppakorn R, Kitiyadisai C. Efficacy and safety of rosuvastatin every other day compared with once daily in patients with hypercholesterolemia. Ann Pharmacother 2006; 40: 1917-23.
47. Zhu JR, Tomlinson B, Ro YM, Sim KH, Lee YT, Sriratanasathavorn C. A randomised study comparing the efficacy and safety of rosuvastatin with atorvastatin for achieving lipid goals in clinical practice in Asian patients at high risk of cardiovascular disease (DISCOVERY-Asia study). Curr Med Res Opin 2007; 23: 3055-68.
48. Qu HY, Xiao YW, Jiang GH, Wang ZY, Zhang Y, Zhang M. Effect of atorvastatin versus rosuvastatin on levels of serum lipids, inflammatory markers and adiponectin in patients with hypercholesterolemia. Pharm Res 2009; 26: 958-64.
49. Liu JP, Chow SC. Bridging studies in clinical development. J Biopharm Stat 2002; 12: 359-67.
50. Uyama Y, Shibata T, Nagai N, Hanaoka H, Toyoshima S, Mori K. Successful bridging strategy based on ICH E5 guideline for drugs approved in Japan. Clin Pharmacol Ther 2005; 78: 102-13.
51. Othman AA, Tenero DM, Boyle DA, Eddington ND, Fossler MJ. Population pharmacokinetics of S (-)-carvedilol in healthy volunteers after administration of the immediate-release (IR) and the new controlledrelease (CR) dosage forms of the racemate. AAPS J 2007; 9: E208- 18.
52. Wu KH, Cui YM, Guo JF, Zhou Y, Zhai SD, Cui FD, et al. Population pharmacokinetics of cyclosporine in clinical renal transplant patients. Drug Metab Dispos 2005; 33: 1268-75.